2022年1月-12月

原著論文（英文）

1. Impact of One-Week Administration of Dihydrotestosterone in Rat Anterior Pituitary Gland. Int J Endocrinol.
   Kanasaki H, Tumurbaatar T, Cairang Z, Tumurgan Z, Oride A, Okada H, Kyo S.
   Int J Endocrinol. 2022 Oct 21;2022:9525227. doi: 10.1155/2022/9525227.
2. FOXP4 inhibits squamous differentiation of atypical cells in cervical intraepithelial neoplasia via an ELF3-dependent pathway.
   Matsumoto, T., Iizuka, T., Nakamura, M., Suzuki, T., Yamamoto, M., Ono, M., Kagami, K., Kasama, H., Wakae, K., Muramatsu, M., Horike, S. I., Kyo, S., Yamamoto, Y., Mizumoto, Y., Daikoku, T., & Fujiwara, H.
   Cancer Sci. 2022;10.1111/cas.15489. doi:10.1111/cas.15489
3. Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines.
   Shanta, K., Nakayama, K., Hossain, M. M., Razia, S., Ishibashi, T., Ishikawa, M., Yamashita, H., Kanno, K., Sato, S., Nakayama, S., Otsuki, Y., & Kyo, S.
   Curr Oncol. 2022;29(6):4020-4033. Published 2022 Jun 1. doi:10.3390/curroncol29060321
4. Hyperandrogenism induces proportional changes in the expression of Kiss-1, Tac2, and DynA in hypothalamic KNDy neurons.
   Okada H, Kanasaki H, Tumurbaatar T, Tumurgan Z, Oride A, Kyo S.
   Reprod Biol Endocrinol. 2022;20(1):91. Published 2022 Jun 21. doi:10.1186/s12958-022-00963-w
5. Effect of Muscle Loss but Not Fat Loss during Primary Debulking Surgery and Chemotherapy on Prognosis of Patients with Ovarian Cancer.
   Nakayama N, Nakayama K, Ishibashi T, Katayama S, Kyo S.
   J Clin Med. 2022 Jun 2;11(11):3184. doi: 10.3390/jcm11113184.
6. Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells.
   Dey P, Nakayama K, Razia S, Ishikawa M, Ishibashi T, Yamashita H, Kanno K, Sato S, Kiyono T, Kyo S.
   Cancers (Basel). 2022 Mar 15;14(6):1506. doi: 10.3390/cancers14061506. 
7. Surgical skill and oncological outcome of laparoscopic radical hysterectomy: JGOG1081s-A1, an ancillary analysis of the Japanese Gynecologic Oncology Group Study JGOG1081.
   Kobayashi E, Nakatani E, Tanaka T, Yosuke K, Kanao H, Shiki Y, Kotani Y, Hoshiba T, Minami R, Yoshida H, Kyo S, Yorimitsu M, Yamashita T, Hasegawa T, Matsuura T, Kagami S, Fujioka T, Hirohiko T, Nishio S, Takekuma M, Mikami M, Enomoto T.
   Gynecol Oncol. 2022 Feb 24:S0090-8258(22)00089-0. doi: 10.1016/j.ygyno.2022.02.005. Epub ahead of print.
8. Ovarian endometrioid and Clear Cell Carcinomas with Low Prevalence of Microsatellite Instability: A Unique Subset of Ovarian Carcinomas Could Benefit from Combination Therapy with Immune Checkpoint Inhibitors and Other Anticancer Agents.
   Nonomura Y, Nakayama K, Nakamura K, Razia S, Yamashita H, Ishibashi T, Ishikawa M, Sato S, Nakayama S, Otsuki Y, Kyo S.
   Healthcare (Basel). 2022 Apr 7;10(4):694. doi: 10.3390/healthcare10040694.
9. Mutation Profiles of Ovarian Seromucinous Borderline Tumors in Japanese Patients.
   Sasamori H, Nakayama K, Razia S, Yamashita H, Ishibashi T, Ishikawa M, Sato S, Nakayama S, Otsuki Y, Fujiwaki R, Ishikawa N, Kyo S.
   Curr Oncol. 2022 May 18;29(5):3658-3667. doi: 10.3390/curroncol29050294.

総説論文（英文）

1. Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance.
   Kyo S, Kanno K, Takakura M, Yamashita H, Ishikawa M, Ishibashi T, Sato S, Nakayama K.
   Cancers (Basel). 2022 May 19;14(10):2504. doi: 10.3390/cancers14102504.